Day 1 of Land of Lakes kicked off today with introduction to complexities of the Cell and gene therapies, risk assessments and proactive interactions with regulatory agencies to develop a fit for purpose bioanalytical strategy for such therapies. The adaptation of LCMS based assays to detect oligonucleotide based modalities and micro-sampling challenges and their application for pediatric blood collection was also discussed The day ended with 3 rapid fire talks discussing detection approaches for nucleic acids and liposome associated mRNA as well as cyclic peptides.
------------------------------
Vibha Jawa
Executive Director
Nonclinical Disposition and Bioanalysis
Bristol-Myers Squibb
Princeton,NJ
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------